Bone loss prevention drug showing promise in advanced prostate cancer

September 02, 2003

Oral sodium clodronate may slow the development of symptomatic bone metastases and reduce the risk of death in men with advanced prostate cancer, according to a randomized controlled trial in the September 3 issue of the Journal of the National Cancer Institute.

Prostate cancer spreads most commonly to the bone, and bone metastases affect at least 85% of men with advanced prostate cancer. Bisphosphonates, including sodium clodronate, reduce bone loss. In the early 1990s, researchers in the United Kingdom initiated two phase III trials to examine the benefit of bisphosphonates in men with advanced prostate cancer. The results of one of these trials is now being reported.

David P. Dearnaley, M.D., of the Institute of Cancer Research and Royal Marsden Hospital in Sutton, United Kingdom; Matthew R. Sydes, M.Sc., of the Medical Research Council Clinical Trials Unit in London; and their colleagues randomly assigned 311 men who were starting or responding to hormone therapy for bone metastases to receive either oral sodium clodronate or a placebo for up to 3 years.

After approximately 5 years of follow up, men in the active treatment group had a 21% reduction in the risk of symptomatic bone progression and a 20% reduction in the risk of death, compared with men in the placebo group. However, these findings were not statistically significant. The authors note several limitations to the study, such as the small population size and the use of an oral rather than an intravenous bisphosphonate. Oral bisphosphonates are poorly absorbed by the body.

Patients in the sodium clodronate group did have a statistically significant 29% increase in the time before their performance status deteriorated. However, men who received sodium clodronate had a 71% greater risk of side effects. These effects were reversed when the drug dose was modified. A subgroup analysis suggested that clodronate might be more effective in men with more recently diagnosed disease.

"Further data are needed that reflect the availability of the newer, more potent bisphosphonates as well as the changing patterns of care for men with prostate cancer," the authors write, adding that more research will help to identify appropriate patient populations for treatment and to determine the appropriate type, dose, and duration of bisphosphonate therapy. Preliminary results from the parallel study should be available next year.

In an accompanying editorial, Fred Saad, M.D., of the University of Montreal Hospital Center in Canada, says that although the current findings are not statistically significant, they provide "at least some evidence that starting bisphosphonates earlier in the metastatic state may give better results."

"Research into the earlier use of bisphosphonates in metastatic prostate cancer as well as into the potential of bisphosphonates to actually prevent metastases is ongoing," he writes. "With a better understanding of the role of bisphosphonates in treatment-induced bone loss, prevention and treatment of metastases, and antitumor effects, it is most likely that the role they play will expand in the management of advanced prostate cancer."
-end-
Contact: David Dearnaley, Royal Marsden Hospital 44-208-661-3271, davidd@icr.ac.uk, or the Medical Research Council press office, 44-207-637- 6011.

Editorial: Fred Saad, University of Montreal Hospital Center, 514-890-8000 ext. 27466, fred.saad.chum@ssss.gouv.qc.ca.

Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson ACR, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst 2003;95:1300-11.

Editorial: Saad F. Bisphosphonates in prostate cancer: Where are we and where should we go? J Natl Cancer Inst 2003;95:1262-3.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.